If you wonder whether Abbott Laboratories (NYSE: ABT) is a good buy in Q2 2025, the answer is yes. The company’s management, portfolio, cash flow, capital return, and pipeline are why. The stock price came under pressure in July because the Q3 guidance update wasn’t better than what the market expected.
Sound crazy, but it's true: the robust outlook wasn’t enough to keep speculators interested, but it isn’t the speculators that matter in the long term. What matters in the long term is that the company’s growth trajectory is positive, supporting a robust capital outlook that includes dividends and share repurchases.
